Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

LUZP1 Controls Cell Division, Migration and Invasion Through Regulation of the Actin Cytoskeleton

  • Bozal Basterra, Laura
  • González Santamarta, María
  • Muratore, Veronica
  • Martín Martín, Natalia
  • Ercilla Eguiarte, Amaia
  • Rodríguez Pérez, José Antonio
  • Carracedo Pérez, Arkaitz
  • Sutherland, James D.
  • Barrio Olano, María Rosa
LUZP1 is a centrosomal and actin cytoskeleton-localizing protein that regulates both ciliogenesis and actin filament bundling. As the cytoskeleton and cilia are implicated in metastasis and tumor suppression, we examined roles for LUZP1 in the context of cancer. Here we show that LUZP1 exhibits frequent genomic aberrations in cancer, with a predominance of gene deletions. Furthermore, we demonstrate that CRISPR/Cas9-mediated loss of Luzp1 in mouse fibroblasts promotes cell migration and invasion features, reduces cell viability, and increases cell apoptosis, centriole numbers, and nuclear size while altering the actin cytoskeleton. Loss of Luzp1 also induced changes to ACTR3 (Actin Related Protein 3, also known as ARP3) and phospho-cofilin ratios, suggesting regulatory roles in actin polymerization, beyond its role in filament bundling. Our results point to an unprecedented role for LUZP1 in the regulation of cancer features through the control of actin cytoskeleton., We are grateful to the Fundacion Inocente, Inocente for their support. We also acknowledge funding by the grants BFU2017-84653-P (MINECO/FEDER, EU), SEV-2016-0644 (Severo Ochoa Excellence Program), 765445-EU (UbiCODE Program), SAF2017-90900-REDT (UBIRed Program), and IT1165-19 (Basque Country Government). Additional support was provided by the Department of Industry, Tourism, and Trade of the Basque Country Government (Elkartek Research Programs) and by the Innovation Technology Department of the Bizkaia County. LB-B acknowledges POSTD19048BOZA (Fundacion Cientifica AECC). VM acknowledges PRE2018086230 (MINECO/FEDER, EU). AC acknowledges the Basque Department of education (IKERTALDE IT1106-16), the MCIU [PID2019-108787RB-I00 (FEDER/EU)], the AECC (IDEAS175CARR; GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/and the European Research Council (Starting Grant 336343, PoC 754627, Consolidator grant 819242). CIBERONC was co-funded with FEDER funds. We are also grateful to Maria Vivanco's lab for providing reagents.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

  • Palomo Irigoyen, Marta
  • Pérez Andrés, Encarni
  • Iruarrizaga Lejarreta, Marta
  • Barreira Manrique, Adrián
  • Tamayo Caro, Miguel
  • Vila Vecilla, Laura
  • Moreno Cugnon, Leire
  • Beitia, Nagore
  • Medrano, Daniela
  • Fernández Ramos, David
  • Lozano, Juan José
  • Okawa, Satoshi
  • Lavín, José L.
  • Martín Martín, Natalia
  • Sutherland, James D.
  • Gutiérez de Juan, Virginia
  • González López, Monika
  • Macías Cámara, Nuria
  • Mosén Ansorena, David
  • Laraba, Liyam
  • Hanemann, C. Oliver
  • Ercolano, Emanuela
  • Parkinson, David B.
  • Schultz, Christopher W.
  • Araúzo Bravo, Marcos J.
  • Ascensión, Alex M.
  • Gerovska, Daniela
  • Iribar López, Haizea
  • Izeta Permisán, Ander
  • Pytel, Peter
  • Krastel, Philipp
  • Provenzani, Alessandro
  • Seneci, Pierfausto
  • Carrasco, Ruben D.
  • Del Sol, Antonio
  • Martínez Chantar, María Luz
  • Barrio Olano, María Rosa
  • Serra, Eduard
  • Lazaro, Conxi
  • Flanagan, Adrienne M.
  • Gorospe, Myriam
  • Ratner, Nancy
  • Aransay Bañares, Ana María
  • Carracedo Pérez, Arkaitz
  • Varela Rey, Marta
  • Woodhoo, Ashwin
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/beta-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment., This work was funded by grants to AW from the Spanish Association Against Cancer (AECC; JP Vizcaya); Spanish Ministry of Science, Innovation and Universities (MCIU)/Agencia Estatal de Investigacion (AEI)/European Regional Development Fund (FEDER), European Union (EU) (Subprograma Ramon y Cajal RYC2010-06901; Proyectos Retos Investigacion RTI2018-097503-B-I00, SAF2015-65360-R; Proyectos Explora Ciencia SAF2015-72416-EXP; Proyectos Europa Excelencia SAF2015-62588-ERC); the BBVA Foundation; Basque Department of Industry, Tourism and Trade (Elkartek) and Education (PI2013-46); Fundacion Vasca de Innovacion e Investigacion Sanitarias EiTB Maratoia (BIO13/CI/015); the Neurofibromatosis Therapeutic Acceleration Program; and the European Research Council (consolidator grant under the EU's Horizon 2020 research and innovation programme; grant agreement 865157). MVR is grateful for the support of a 2017 Leonardo Grant for Researchers and Cultural Creators (BBVA Foundation), Accion Estrategica Ciber Emergentes 2018 (Ciberehd-ISCIII), and Gilead Sciences International Research Scholars Program in Liver Disease. The work of AC is supported by the Basque Department of Industry, Tourism and Trade (Elkartek) and Education (IKERTALDE IT1106-16); the BBVA Foundation; the MCIU/AEI (SAF2016-79381-R [FEDER/EU]; Severo Ochoa Excellence Accreditation SEV-2016-0644; Excellence Networks SAF20168-1975-REDT); the European Training Networks Project (H2020-MSCA-ITN-308 2016 721532); the AECC (IDEAS175CARR, GCTRA18006CARR); La Caixa Foundation (HR17-00094); and the European Research Council (Starting Grant 336343, PoC 754627). MG was supported by the Intramural Research Program of the National Institute on Aging, NIH. MPI is grateful for the support of the Basque Government of Education fellowship. MTC is grateful for the support of "Ayudas para contratos predoctorales para la formacion de doctores" (MCIU/AEI/FEDER, EU). COH acknowledges funding from Brain Tumour Research. RB acknowledges MCIU/AEI/FEDER, EU (BFU2014-52282-P and BFU2017-84653-P). ES and CL are supported by the Carlos III National Health Institute funded by FEDER funds - a way to build Europe (CIBERONC) and the Government of Catalonia (2017SGR496). MLM-C acknowledges support from MCIU/AEI/FEDER, EU (SAF2017-87301-R); Asociacion Espanola Contra El Cancer (AECC); AECC Canceres Raros; BBVA Biomedicina (UMBRELLA); and La CAIXA Foundation (LCF/PR/HP17/52190004). AP was supported by Associazione Italiana Ricerca sul Cancro (AIRC; IG 2018 Id.21548). CIBERehd is funded by the Instituto de Salud Carlos III. We thank MCIU for the Severo Ochoa Excellence Accreditation (SEV-2016-0644).
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Identification of proximal SUMO-dependent interactors using SUMO-ID

  • Barroso Gomila, Orhi
  • Trulsson, Erik
  • Muratore, Veronica
  • Canosa, Iñigo
  • Merino Cacho, Laura
  • Cortázar, Ana Rosa
  • Pérez Fernández, Coralia
  • Azkargorta, Mikel
  • Iloro, Ibon
  • Carracedo Pérez, Arkaitz
  • Aransay Bañares, Ana María
  • Elortza, Felix
  • Mayor Martínez, Ugo
  • Verteegal, Alfred C. O.
  • Barrio Olano, María Rosa
  • Sutherland, James D.
[EN]The fast dynamics and reversibility of posttranslational modifications by the ubiquitin family pose significant challenges for research. Here we present SUMO-ID, a technology that merges proximity biotinylation by TurboID and protein-fragment complementation to find SUMO-dependent interactors of proteins of interest. We develop an optimized split-TurboID version and show SUMO interaction-dependent labelling of proteins proximal to PML and RANGAP1. SUMO-dependent interactors of PML are involved in transcription, DNA damage, stress response and SUMO modification and are highly enriched in SUMO Interacting Motifs, but may only represent a subset of the total PML proximal proteome. Likewise, SUMO-ID also allow us to identify interactors of SUMOylated SALL1, a less characterized SUMO substrate. Furthermore, using TP53 as a substrate, we identify SUMO1, SUMO2 and Ubiquitin preferential interactors. Thus, SUMO-ID is a powerful tool that allows to study the consequences of SUMO-dependent interactions, and may further unravel the complexity of the ubiquitin code., We are thankful to Iraide Escobes for her work in the Proteomics Platform at CIC bioGUNE and Arnoud de Ru in the Center for Proteomics and Metabolomics at the LUMC. O.B.-G., F.T., R.B. and A.C.O.V. acknowledge funding by the grant 765445-EU (UbiCODE Program). R.B. acknowledges funding by grants BFU2017-84653-P and PID2020-114178GB-I00 (MINECO/FEDER, EU), SEV-2016-0644 (Severo Ochoa Excellence Program), SAF2017-90900-REDT (UBIRed Program) and IT1165-19 (Basque Country Government). Additional support was provided by the Department of Industry, Tourism, and Trade of the Basque Country Government (Elkartek Research Programs) and by the Innovation Technology Department of the Bizkaia County. VM acknowledges FPI grant PRE2018-086230 (MINECO/FEDER, EU). F.E. is at Proteomics Platform, member of ProteoRed-ISCIII (PT13/0001/0027). F.E. and A.M.A. acknowledge CIBERehd. A.C. acknowledges the Basque Department of education (IKERTALDE IT1106-16), the MCIU (PID2019-108787RB-I00 (FEDER/EU), Severo Ochoa Excellence Accreditation SEV-2016-0644, Excellence Networks RED2018-102769-T), the AECC (GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17, and the European Research Council (Starting Grant 336343, PoC 754627, Consolidator grant 819242). CIBERONC was co-funded with FEDER funds. U.M. acknowledges the Basque Government Department of Education (IT1165-19) and the Spanish MCIU (SAF2016-76898-P (FEDER/EU)).
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga García, Patricia
  • Caro Maldonado, Alfredo
  • Fernandez Ruiz, Sonia
  • Salvador, Fernando
  • Martín Martín, Natalia
  • Zabala Letona, Amaia
  • Nuñez Olle, Marc
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano, José Miguel
  • Talamillo, Ana
  • Carreira, Suzanne
  • Gurel, Bora
  • Cortazar, Ana Rosa
  • Guiu, Marc
  • López, Jose I.
  • Martínez Romero, Anabel
  • Astobiza, Ianire
  • Valcarcel Jimenez, Lorea
  • Lorente, Mar
  • Arruabarrena-Aristorena, Amaia
  • Velasco, Guillermo
  • Gomez Muñoz, Antonio
  • Suarez Cabrera, Cristian
  • Lodewijk, Iris
  • Flores, Juana M.
  • Sutherland, James David
  • Barrio, Rosa
  • Bono, Johann Sebastian de
  • Paramio, Jesús M.
  • Trka, Jan
  • Graupera i Garcia-Milà, Mariona
  • Gomis i Cabré, Roger
  • Carracedo, Arkaitz
Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkbl alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1(K781), was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Low-dose statin treatment increases prostate cancer aggressiveness

  • Caro Maldonado, Alfredo
  • Camacho, Laura
  • Zabala Letona, Amaia
  • Torrano, Verónica
  • Fernández Ruiz, Sonia
  • Zamacola-Bascaran, Kepa
  • Arreal, Leire
  • Valcarcel Jimenez, Lorea
  • Martín-Martín, Natalia
  • Flores, Juana María
  • Cortazar, Ana Rosa
  • Zúñiga García, Patricia
  • Arruabarrena-Aristorena, Amaia
  • Guillaumond, Fabienne
  • Cabrera, Diana
  • Falcón Pérez, Juan M.
  • Aransay, Ana M.
  • Gomez-Muñoz, Antonio
  • Olivan Riera, Mireia
  • Morote, Juan
  • Carracedo, Arkaitz
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

  • Palomo Irigoyen, Marta
  • Pérez Andrés, Encarni
  • Iruarrizaga Lejarreta, Marta
  • Barreira Manrique, Adrián
  • Tamayo Caro, Miguel
  • Vila Vecilla, Laura
  • Moreno Cugnon, Leire
  • Beitia, Nagore
  • Medrano, Daniela
  • Fernández Ramos, David
  • Lozano Salvatella, Juan José
  • Okawa, Satoshi
  • Lavín, José L.
  • Martín Martín, Natalia
  • Sutherland, James David
  • Guitiérez de Juan, Virginia
  • González López, Monika
  • Macías Cámara, Nuria
  • Mosén Ansorena, David
  • Laraba, Liyam
  • Hanemann, C. Oliver
  • Ercolano, Emanuela
  • Parkinson, David B.
  • Schultz, Christopher W.
  • Araúzo Bravo, Marcos J.
  • Ascensión, Alex M.
  • Gerovska, Daniela
  • Iribar, Haizea
  • Izeta, Ander
  • Pytel, Peter
  • Krastel, Philipp
  • Provenzani, Alessandro
  • Seneci, Pierfausto
  • Carrasco, Ruben D.
  • Sol, Antonio Del
  • Martínez Chantar, Maria Luz
  • Barrio, Rosa
  • Serra Arenas, Eduard
  • Lázaro García, Conxi
  • Flanagan, Adrienne M.
  • Gorospe, Myriam
  • Ratner, Nancy
  • Aransay, Ana M.
  • Carracedo, Arkaitz
  • Varela Rey, Marta
  • Woodhoo, Ashwin
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/beta-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  • Zabala Letona, Amaia
  • Arruabarrena-Aristorena, Amaia
  • Martín Martín, Natalia
  • Fernández Ruiz, Sonia
  • Sutherland, James David
  • Clasquin, Michelle
  • Tomas Cortazar, Julen
  • Jimenez, Jose
  • Torres, Inés de
  • Quang, Phong
  • Ximénez Embún, Pilar
  • Bago, Ruzica
  • Ugalde Olano, Aitziber
  • Loizaga Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda Urzaiz, Miguel
  • Torrano, Verónica
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Cendon, Ylenia
  • Castro, Elena
  • Murray, Stuart
  • Revandkar, Ajinkya
  • Alimonti, Andrea
  • Zhang, Yinan
  • Barnett, Amelia
  • Lein, Gina
  • Pirman, David
  • Cortazar, Ana Rosa
  • Arreal, Leire
  • Prudkin, Ludmila
  • Astobiza, Ianire
  • Valcarcel Jimenez, Lorea
  • Zuñiga García, Patricia
  • Fernandez-Dominguez, Itziar
  • Piva, Marco
  • Caro Maldonado, Alfredo
  • Sánchez Mosquera, Pilar
  • Castillo Martin, Mireia
  • Serra Elizalde, Violeta
  • Beraza, Naiara
  • Gentilella, Antonio
  • Thomas, George
  • Azkargorta, Mikel
  • Elortza, Felix
  • Farràs, Rosa
  • Olmos, David
  • Efeyan, Alejo
  • Anguita, Juan
  • Muñoz, Javier
  • Falcón Pérez, Juan Manuel
  • Barrio, Rosa
  • Macarulla, Teresa
  • Mato, José M.
  • Martínez Chantar, Maria Luz
  • Cordon Cardo, Carlos
  • Aransay, Ana M.
  • Marks, Kevin
  • Baselga Torres, Josep, 1959-2021
  • Tabernero Caturla, Josep
  • Nuciforo, Paolo
  • Manning, Brendan D.
  • Marjon, Katya
  • Carracedo, Arkaitz
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation1,2. Here we show that mechanistic target of rapamycin complex 1 (mTORC1) regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. By using integrative metabolomics in a mouse model3 and human biopsies4 of prostate cancer, we identify alterations in tumours affecting the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation is validated in mouse and human cancer specimens. AMD1 is upregulated in human prostate cancer with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus5 exhibit a predominant decrease in AMD1 immunoreactivity that is associated with a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer

  • Pey, Jon
  • San José-Eneriz, Edurne
  • Ochoa, María Carmen
  • Apaolaza, Iñigo
  • Atauri, Pedro de
  • Rubio, Angel
  • Cendoya, Xabier
  • Miranda, Estíbaliz
  • Garate, Leire
  • Cascante i Serratosa, Marta
  • Carracedo, Arkaitz
  • Agirre, Xabier
  • Prosper, Felipe
  • Planes, Francisco J.
Constraint-based modeling for genome-scale metabolic networks has emerged in the last years as a promising approach to elucidate drug targets in cancer. Beyond the canonical biosynthetic routes to produce biomass, it is of key importance to focus on metabolic routes that sustain the proliferative capacity through the regulation of other biological means in order to improve in-silico gene essentiality analyses. Polyamines are polycations with central roles in cancer cell proliferation, through the regulation of transcription and translation among other things, but are typically neglected in in silico cancer metabolic models. In this study, we analysed essential genes for the biosynthesis of polyamines. Our analysis corroborates the importance of previously known regulators of the pathway, such as Adenosylmethionine Decarboxylase 1 (AMD1) and uncovers novel enzymes predicted to be relevant for polyamine homeostasis. We focused on Adenine phosphoribosyltransferase (APRT) and demonstrated the detrimental consequence of APRT gene silencing on diferent leukaemia cell lines. Our results highlight the importance of revisiting the metabolic models used for in-silico gene essentiality analyses in order to maximize the potential for drug target identifcation in cancer
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multiplex SERS Detection of Metabolic Alterations in Tumor Extracellular Media

  • Plou, Javier
  • García, Isabel
  • Charconnet, Mathias
  • Astobiza, Ianire
  • García Astrain, Clara
  • Matricardi, Cristiano
  • Mihi, Agustín
  • Carracedo, Arkaitz
  • Liz-Marzán, Luis Manuel
The composition and intercellular interactions of tumor cells in the tissues dictate the biochemical and metabolic properties of the tumor microenvironment. The metabolic rewiring has a profound impact on the properties of the microenvironment, to an extent that monitoring such perturbations could harbor diagnostic and therapeutic relevance. A growing interest in these phenomena has inspired the development of novel technologies with sufficient sensitivity and resolution to monitor metabolic alterations in the tumor microenvironment. In this context, surface‐enhanced Raman scattering (SERS) can be used for the label‐free detection and imaging of diverse molecules of interest among extracellular components. Herein, the application of nanostructured plasmonic substrates comprising Au nanoparticles, self‐assembled as ordered superlattices, to the precise SERS detection of selected tumor metabolites, is presented. The potential of this technology is first demonstrated through the analysis of kynurenine, a secreted immunomodulatory derivative of the tumor metabolism and the related molecules tryptophan and purine derivatives. SERS facilitates the unambiguous identification of trace metabolites and allows the multiplex detection of their characteristic fingerprints under different conditions. Finally, the effective plasmonic SERS substrate is combined with a hydrogel‐based three‐dimensional cancer model, which recreates the tumor microenvironment, for the real‐time imaging of metabolite alterations and cytotoxic effects on tumor cells., J.P. acknowledges an FPU fellowship from the Spanish Ministry of Science, Innovation and Universities. L.M.L.‐M. acknowledges funding from the European Research Council (ERC AdG 787510, 4DbioSERS) and the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (Grant No. MDM‐2017‐0720). C.G.‐A. acknowledges a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (FJCI‐2016‐28887). The authors thank Dr. J. Calvo and Dr. D. Otaegui at CIC biomaGUNE for support with LC/ESI‐HRMS measurements. The work of A.C. was supported by the Basque Department of Industry, Tourism and Trade (Elkartek), and the department of education (IKERTALDE IT1106‐16, also participated by A. Gomez‐Muñoz), the BBVA foundation, the MINECO (SAF2016‐79381‐R (FEDER/EU); Severo Ochoa Excellence Program SEV‐2016‐0644‐18‐1; Excellence Networks SAF2016‐81975‐REDT), European Training Networks Project (H2020‐MSCA‐ITN‐308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (HR17‐00094), and the European Research Council (starting Grant 336343, PoC 754627). CIBERONC was co‐funded with FEDER funds and funded by ISCIII. A.M. acknowledges funding from the European Research Council (Consolidator Grant 819242) and the Spanish Ministry of Science, Innovation and Universities for the excellence program SEV‐2015‐0496.J.P. acknowledges an FPU fellowship from the Spanish Ministry of Science, Innovation and Universities. L.M.L.‐M. acknowledges funding from the European Research Council (ERC AdG 787510, 4DbioSERS) and the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (Grant No. MDM‐2017‐0720). C.G.‐A. acknowledges a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (FJCI‐2016‐28887). The authors thank Dr. J. Calvo and Dr. D. Otaegui at CIC biomaGUNE for support with LC/ESI‐HRMS measurements. The work of A.C. was supported by the Basque Department of Industry, Tourism and Trade (Elkartek), and the department of education (IKERTALDE IT1106‐16, also participated by A. Gomez‐Muñoz), the BBVA foundation, the MINECO (SAF2016‐79381‐R (FEDER/EU); Severo Ochoa Excellence Program SEV‐2016‐0644‐18‐1; Excellence Networks SAF2016‐81975‐REDT), European Training Networks Project (H2020‐MSCA‐ITN‐308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (HR17‐00094), and the European Research Council (starting Grant 336343, PoC 754627). CIBERONC was co‐funded with FEDER funds and funded by ISCIII. A.M. acknowledges funding from the European Research Council (Consolidator Grant 819242) and the Spanish Ministry of Science, Innovation and Universities for the excellence program SEV‐2015‐0496., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cancertool: A visualization and representation interface to exploit cancer datasets

  • Cortázar, Ana R.
  • Torrano, Verónica
  • Martín-Martín, Natalia
  • Caro-Maldonado, Alfredo
  • Camacho, Laura
  • Hermanova, Ivana
  • Guruceaga, Elizabeth
  • Lorenzo-Martín, L. Francisco
  • Caloto, Rubén
  • Gomis, Roger R.
  • Apaolaza, Iñigo
  • Quesada, Víctor
  • Trka, Jan
  • Gómez-Muñoz, Antonio
  • Vincent, Silvestre
  • Bustelo, Xosé R.
  • Planes, Francisco J.
  • Aransay, Ana M.
  • Carracedo, Arkaitz
With the advent of OMICs technologies, both individual research groups and consortia have spear-headed the characterization of human samples of multiple pathophysiologic origins, resulting in thousands of archived genomes and transcriptomes. Although a variety of web tools are now available to extract information from OMICs data, their utility has been limited by the capacity of nonbioinformatician researchers to exploit the information. To address this problem, we have developed CANCERTOOL, a web-based interface that aims to overcome the major limitations of public transcriptomics dataset analysis for highly prevalent types of cancer (breast, prostate, lung, and colorectal). CANCERTOOL provides rapid and comprehensive visualization of gene expression data for the gene(s) of interest in well-annotated cancer datasets. This visualization is accompanied by generation of reports customized to the interest of the researcher (e.g., editable figures, detailed statistical analyses, and access to raw data for reanalysis). It also carries out gene-to-gene correlations in multiple datasets at the same time or using preset patient groups. Finally, this new tool solves the time-consuming task of performing functional enrichment analysis with gene sets of interest using up to 11 different databases at the same time. Collectively, CANCERTOOL represents a simple and freely accessible interface to interrogate well-annotated datasets and obtain publishable representations that can contribute to refinement and guidance of cancer-related investigations at all levels of hypotheses and design., We are grateful to Iñaki Lazaro for the design of the tumor type logos, Evarist Planet and Antoni Berenguer for insightful discussions, and the Carracedo lab for valuable input. V. Torrano is funded by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the AECC J.P. Bizkaia and the Basque Department of Health (2016111109). The work of A. Carracedo is supported by the Basque Department of Industry, Tourism and Trade (Etortek) and the Department of Education (IKERTALDE IT1106-16, also participated by A. Gomez-Muñoz), the BBVA Foundation, the MINECO [SAF2016-79381-R (FEDER/EU)]; Severo Ochoa Excellence Accreditation SEV-2016-0644; Excellence Networks (SAF2016-81975-REDT), European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the AECC IDEAS16 (IDEAS175CARR), and the European Research Council (Starting Grant 336343, PoC 754627). CIBERONC was cofunded with FEDER funds. The work of A. Aransay is supported by the Basque Department of Industry, Tourism and Trade (Etortek and Elkartek Programs), the Innovation Technology Department of Bizkaia County, CIBERehd Network, and Spanish MINECO the Severo Ochoa Excellence Accreditation (SEV-2016-0644). I. Apaolaza is funded by a Basque Government predoctoral grant (PRE_2017_2_0028). X.R. Bustelo is supported by grants from the Castilla-León Government (BIO/SA01/15, CSI049U16), Spanish Ministry of Economy and Competitiveness (MINECO; SAF2015-64556-R), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and the Spanish Society against Cancer (GC16173472GARC). Funding from MINECO to X.R. Bustelo is partially contributed by the European Regional Development Fund. The work of F.J. Planes is supported by the MINECO (BIO2016-77998-R) and ELKARTEK Programme of the Basque Government (KK-2016/00026).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  • Zabala Letona, Amaia
  • Arruabarrena-Aristorena, Amaia
  • Martín Martín, Natalia
  • Fernández Ruiz, Sonia
  • Sutherland, James David
  • Clasquin, Michelle
  • Tomas Cortazar, Julen
  • Jimenez, Jose
  • Torres, Inés de
  • Quang, Phong
  • Ximénez Embún, Pilar
  • Bago, Ruzica
  • Ugalde Olano, Aitziber
  • Loizaga Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda Urzaiz, Miguel
  • Torrano, Verónica
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Cendon, Ylenia
  • Castro, Elena
  • Murray, Stuart
  • Revandkar, Ajinkya
  • Alimonti, Andrea
  • Zhang, Yinan
  • Barnett, Amelia
  • Lein, Gina
  • Pirman, David
  • Cortazar, Ana Rosa
  • Arreal, Leire
  • Prudkin, Ludmila
  • Astobiza, Ianire
  • Valcarcel Jimenez, Lorea
  • Zuñiga García, Patricia
  • Fernandez-Dominguez, Itziar
  • Piva, Marco
  • Caro Maldonado, Alfredo
  • Sánchez Mosquera, Pilar
  • Castillo Martin, Mireia
  • Serra Elizalde, Violeta
  • Beraza, Naiara
  • Gentilella, Antonio
  • Thomas, George
  • Azkargorta, Mikel
  • Elortza, Felix
  • Farràs, Rosa
  • Olmos, David
  • Efeyan, Alejo
  • Anguita, Juan
  • Muñoz, Javier
  • Falcón Pérez, Juan Manuel
  • Barrio, Rosa
  • Macarulla, Teresa
  • Mato, José M.
  • Martínez Chantar, Maria Luz
  • Cordon Cardo, Carlos
  • Aransay, Ana M.
  • Marks, Kevin
  • Baselga Torres, Josep, 1959-2021
  • Tabernero Caturla, Josep
  • Nuciforo, Paolo
  • Manning, Brendan D.
  • Marjon, Katya
  • Carracedo, Arkaitz
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation1,2. Here we show that mechanistic target of rapamycin complex 1 (mTORC1) regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. By using integrative metabolomics in a mouse model3 and human biopsies4 of prostate cancer, we identify alterations in tumours affecting the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation is validated in mouse and human cancer specimens. AMD1 is upregulated in human prostate cancer with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus5 exhibit a predominant decrease in AMD1 immunoreactivity that is associated with a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga García, Patricia
  • Caro Maldonado, Alfredo
  • Fernandez Ruiz, Sonia
  • Salvador, Fernando
  • Martín Martín, Natalia
  • Zabala Letona, Amaia
  • Nuñez Olle, Marc
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano, José Miguel
  • Talamillo, Ana
  • Carreira, Suzanne
  • Gurel, Bora
  • Cortazar, Ana Rosa
  • Guiu, Marc
  • López, Jose I.
  • Martínez Romero, Anabel
  • Astobiza, Ianire
  • Valcarcel Jimenez, Lorea
  • Lorente, Mar
  • Arruabarrena-Aristorena, Amaia
  • Velasco, Guillermo
  • Gomez Muñoz, Antonio
  • Suarez Cabrera, Cristian
  • Lodewijk, Iris
  • Flores, Juana M.
  • Sutherland, James David
  • Barrio, Rosa
  • Bono, Johann Sebastian de
  • Paramio, Jesús M.
  • Trka, Jan
  • Graupera i Garcia-Milà, Mariona
  • Gomis i Cabré, Roger
  • Carracedo, Arkaitz
Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkbl alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1(K781), was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

  • Palomo Irigoyen, Marta
  • Pérez Andrés, Encarni
  • Iruarrizaga Lejarreta, Marta
  • Barreira Manrique, Adrián
  • Tamayo Caro, Miguel
  • Vila Vecilla, Laura
  • Moreno Cugnon, Leire
  • Beitia, Nagore
  • Medrano, Daniela
  • Fernández Ramos, David
  • Lozano Salvatella, Juan José
  • Okawa, Satoshi
  • Lavín, José L.
  • Martín Martín, Natalia
  • Sutherland, James David
  • Guitiérez de Juan, Virginia
  • González López, Monika
  • Macías Cámara, Nuria
  • Mosén Ansorena, David
  • Laraba, Liyam
  • Hanemann, C. Oliver
  • Ercolano, Emanuela
  • Parkinson, David B.
  • Schultz, Christopher W.
  • Araúzo Bravo, Marcos J.
  • Ascensión, Alex M.
  • Gerovska, Daniela
  • Iribar, Haizea
  • Izeta, Ander
  • Pytel, Peter
  • Krastel, Philipp
  • Provenzani, Alessandro
  • Seneci, Pierfausto
  • Carrasco, Ruben D.
  • Sol, Antonio Del
  • Martínez Chantar, Maria Luz
  • Barrio, Rosa
  • Serra Arenas, Eduard
  • Lázaro García, Conxi
  • Flanagan, Adrienne M.
  • Gorospe, Myriam
  • Ratner, Nancy
  • Aransay, Ana M.
  • Carracedo, Arkaitz
  • Varela Rey, Marta
  • Woodhoo, Ashwin
Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/beta-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Low-dose statin treatment increases prostate cancer aggressiveness

  • Caro Maldonado, Alfredo
  • Camacho, Laura
  • Zabala Letona, Amaia
  • Torrano, Verónica
  • Fernández Ruiz, Sonia
  • Zamacola-Bascaran, Kepa
  • Arreal, Leire
  • Valcárcel-Jiménez, Lorea
  • Martín-Martín, Natalia
  • Flores, Juana María
  • Cortazar, Ana Rosa
  • Zúñiga García, Patricia
  • Arruabarrena-Aristorena, Amaia
  • Guillaumond, Fabienne
  • Cabrera, Diana
  • Falcón Pérez, Juan M.
  • Aransay, Ana M.
  • Gomez-Muñoz, Antonio
  • Olivan Riera, Mireia
  • Morote, Juan
  • Carracedo, Arkaitz
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer

  • Pey, Jon
  • San José-Eneriz, Edurne
  • Ochoa, María Carmen
  • Apaolaza, Iñigo
  • Atauri, Pedro de
  • Rubio, Angel
  • Cendoya, Xabier
  • Miranda, Estíbaliz
  • Garate, Leire
  • Cascante i Serratosa, Marta
  • Carracedo, Arkaitz
  • Agirre, Xabier
  • Prosper, Felipe
  • Planes, Francisco J.
Constraint-based modeling for genome-scale metabolic networks has emerged in the last years as a promising approach to elucidate drug targets in cancer. Beyond the canonical biosynthetic routes to produce biomass, it is of key importance to focus on metabolic routes that sustain the proliferative capacity through the regulation of other biological means in order to improve in-silico gene essentiality analyses. Polyamines are polycations with central roles in cancer cell proliferation, through the regulation of transcription and translation among other things, but are typically neglected in in silico cancer metabolic models. In this study, we analysed essential genes for the biosynthesis of polyamines. Our analysis corroborates the importance of previously known regulators of the pathway, such as Adenosylmethionine Decarboxylase 1 (AMD1) and uncovers novel enzymes predicted to be relevant for polyamine homeostasis. We focused on Adenine phosphoribosyltransferase (APRT) and demonstrated the detrimental consequence of APRT gene silencing on diferent leukaemia cell lines. Our results highlight the importance of revisiting the metabolic models used for in-silico gene essentiality analyses in order to maximize the potential for drug target identifcation in cancer
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  • Zabala-Letona, Amaia
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Martín Martín, Natalia
  • Fernández Ruiz, Sonia
  • Sutherland, James D.|||0000-0003-3229-793X
  • Clasquin, Michelle
  • Tomás Cortázar, Julen
  • Jiménez, José
  • Torres Ramírez, Inés Ma. de
  • Quang, Phong
  • Ximénez-Embún, Pilar|||0000-0002-2582-9443
  • Bago, Ruzica
  • Ugalde Olano, Aitziber
  • Loizaga Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Torrano, Verónica
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Cendon, Ylenia
  • Castro, Elena|||0000-0002-3691-6454
  • Murray, Stuart
  • Revandkar, Ajinkya
  • Alimonti, Andrea
  • Zhang, Yinan
  • Barnett, Amelia
  • Lein, Gina
  • Pirman, David
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Arreal, Leire
  • Prudkin, Ludmila
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel-Jimenez, Lorea
  • Zúñiga-García, Patricia
  • Fernández Domínguez, Itziar
  • Piva, Marco
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Sánchez Mosquera, Pilar
  • Castillo Martín, Mireia
  • Serra, Violeta|||0000-0001-6620-1065
  • Beraza, Naiara
  • Gentilella, Antonio|||0000-0002-6830-2086
  • Thomas, George|||0000-0002-1236-1714
  • Azkargorta, Mikel
  • Elortza, Felix|||0000-0001-8839-5438
  • Farràs, Rosa
  • Olmos, David
  • Efeyan, Alejo
  • Anguita, Juan
  • Muñoz, Javier|||0000-0003-3288-3496
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Barrio, Rosa|||0000-0002-9663-0669
  • Macarulla Mercadé, Teresa|||0000-0002-5856-4082
  • Mato, José M.
  • Martínez Chantar, Maria L.
  • Cordon Cardo, Carlos
  • Aransay, Ana M.|||0000-0002-8271-612X
  • Marks, Kevin
  • Baselga Torres, Josep
  • Tabernero, Josep|||0000-0002-2495-8139
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Manning, Brendan D.
  • Marjon, Katya
  • Carracedo, Arkaitz|||0000-0001-5957-1260
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation,. Here we show that mTORC1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. Through the use of integrative metabolomics in a mouse model and human biopsies of prostate cancer, we identified alterations in tumours impacting on the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation was validated in murine and human cancer specimens. AMD1 was upregulated in prostate cancer specimens with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus exhibited a predominant decrease in AMD1 immunoreactivity that was associated to a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga-García, Patricia
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Fernandez-Ruiz, Sonia
  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Zabala-Letona, Amaia
  • Nuñez-Olle, Marc|||0000-0002-3593-2591
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Talamillo, Ana
  • Carreira, Suzanne|||0000-0002-5077-5379
  • Gurel, Bora|||0000-0002-5018-8078
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Guiu, Marc|||0000-0002-7083-986X
  • López, Jose I.|||0000-0003-0842-5348
  • Martinez-Romero, Anabel
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel, Lorea|||0000-0002-7309-9924
  • Lorente, Mar|||0000-0003-0982-0956
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Velasco, Guillermo|||0000-0002-1994-2386
  • Gomez Muñoz, Antonio|||0000-0002-2539-016X
  • Suárez-Cabrera, Cristian|||0000-0003-1897-1596
  • Lodewijk, Iris
  • Flores, Juana M.|||0000-0002-7995-4426
  • Sutherland, James D.|||0000-0003-3229-793X
  • Barrio, Rosa|||0000-0002-9663-0669
  • de Bono, Johann S.|||0000-0002-2034-595X
  • Paramio, Jesús M.|||0000-0001-7520-3177
  • Trka, Jan|||0000-0002-9527-8608
  • Graupera, Mariona|||0000-0003-4608-4185
  • Gomis, Roger R.|||0000-0001-6473-2858
  • Carracedo, Arkaitz|||0000-0001-5957-1260
This study unravels an unprecedented murine model of lethal metastatic prostate cancer, based on the combined deletion of Pten and Lkb1. Importantly, minimal activity of LKB1 is sufficient to hamper prostate cancer cell aggressiveness, thus redefining the relationship between gene dosage and tumor suppression. Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1 K78I, was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.